https://www.kynexistx.com https://www.kynexistx.com/news/kynexis-announces-initiation-of-first-in-human-phase-1-study-of-kyn-5356 https://www.kynexistx.com/news/kynexis-announces-positive-topline-results-from-phase-1-study-of-kyn-5356-a-potential-treatment-for-cognitive-impairment-associated-with-schizophrenia-pr https://www.kynexistx.com/news/kynexis-launched-to-advance-precision-therapeutics-for-brain-diseases https://www.kynexistx.com/news/phase-2-first-patient-dosed https://www.kynexistx.com/news/reflections-from-sirs-2026-addressing-cognitive-impairment-in-schizophrenia https://www.kynexistx.com/news/scientific-advisory-board https://www.kynexistx.com/policies/privacy-policy